Syndromes Without a Name Bring Labs an Uphill Battle
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
In early November 2019, the U.S. Food and Drug Administration (FDA) updated a previous safety communication about the potential of biotin to significantly interfere with diagnostic tests. The update reiterates the warning
From - Diagnostic Testing & Emerging Technologies
The notion of empowering patients to take control over their own health care is particularly powerful within the realm of…
By Robert Liles bio
Over the last year, a number of genetic testing fraud investigations and prosecutions have been initiated by…